Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

European Respiratory Journal

Volumn 39, Issue 2, 2012, Pages 366-372

  Girard, N ^a   Sima, C S ^a   Jackman, D M ^b   Sequist, L V ^c   Chen, H ^d   Yang, J C H ^f   Ji, H ^e   Waltman, B ^c   Rosell, R ^g   Taron, M ^g   Zakowski, M F ^a   Ladanyi, M ^a   Riely, G ^a   Pao, W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d FUDAN UNIVERSITY   (China)

^e INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor mutations; Lung cancer; Nomogram; Prediction score; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

ACCURACY; ADULT; ADVANCED CANCER; AGE; AGED; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CANCER CLASSIFICATION; CANCER STAGING; CAUCASIAN; EAST ASIAN; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON 19; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENOTYPE; HISPANIC; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; NOMOGRAM; ONCOGENE K RAS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; TUMOR VOLUME;

ADENOCARCINOMA; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISPANIC AMERICANS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84863010944     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00010111     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, American Cancer Society, 2007.
2. Travis WB.WHO histological classification of tumours of the lung. In: Travis WB, Brambilla A, Muller-Hermelinck HK, et al., eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004; p 10.
3. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 2006; 11: 533-538. (Pubitemid 44186257)
4. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12: 7232-7241. (Pubitemid 46095394)
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311. (Pubitemid 39209661)
6. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-262. (Pubitemid 41779062)
7. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
8. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
9. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
10. Annex I: Summary of Product Characteristics. www.ema.europa. eu/docs/en-GB/document-library/EPAR---Product-Information/ human/001016/ WC500036358.pdf Date last accessed: January 17, 2011. Date last updated: November 7, 2011.
11. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251- 6266.
12. National Comprehensive Cancer Network®. www.nccn.org/ professionals/physician-gls/PDF/nscl.pdf Date last accessed: January 17, 2011. Date last updated: November 7, 2011.
13. Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 2010; 26: 1364-1403.
14. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage III/IV chemonaive NSCLC patients receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745-2753.
15. Zakowski MF, Ladanyi M, Rekhtman N, et al. Reflex testing of lung adenocarcinomas for EGFR and KRAS mutations: the Memorial Sloan-Kettering experience. J Clin Oncol 2008; 26: 22031.
16. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
17. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827.
18. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717. (Pubitemid 27260107)
19. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29: 633-639. (Pubitemid 40577873)
20. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-771. (Pubitemid 28259189)
21. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387. (Pubitemid 26072233)
22. Pao W, Girard N. New driver mutations in non-small cell lung cancer. Lancet Oncol 2011; 12: 175-180.
23. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006; 24: 1700-1704. (Pubitemid 46622141)
24. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
25. Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010; 126: 651-655.
26. Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007; 13: 5763-5768. (Pubitemid 47583901)
27. Dacic S, Shuai Y, Yousem S, et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010; 23: 159-168.
28. Sakamoto H, Shimizu J, Horio Y, et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007; 212: 287-294. (Pubitemid 47010062)
29. Gridelli C, Ciardiello F, Feld R, et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): the TORCH trial. J Clin Oncol 2010; 28: 7508.
30. Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thoracic Oncol 2009; 4: Suppl. 1, S283-S284.